Core Viewpoint - Huazhen Biotechnology (Qingdao) Co., Ltd. (stock code: 02396.HK) listed on the Hong Kong Stock Exchange today, opening below the issue price at HKD 33.80 and closing at HKD 27.00, representing a decline of 29.32% from the final offer price of HKD 38.20 [1][4]. Summary by Relevant Sections Share Issuance and Capital Structure - The total number of shares offered globally was 17,648,800 H-shares, with 1,765,000 shares for public offering in Hong Kong and 15,883,800 shares for international offering [2]. - At the time of listing, the total number of issued shares was 117,657,522 [2]. Financial Details - The final offer price was set at HKD 38.20, resulting in total proceeds of HKD 674.18 million. After deducting estimated listing expenses of HKD 74.36 million, the net proceeds amounted to HKD 599.82 million [4][5]. Use of Proceeds - The net proceeds from the global offering are intended to fund the ongoing clinical development and commercialization of core products Pro-101-1 and Pro-101-2, purchase professional equipment related to R&D and quality control, and cover third-party service fees, personnel costs, and raw material costs for clinical research activities [6]. Company Overview and Product Pipeline - Established in 2012, Huazhen Biotechnology is a biopharmaceutical company based in China, focusing on developing protein drugs for medical needs and market opportunities, particularly in wound healing therapies [6]. - The company has a pipeline of ten candidate products, seven of which are PDGF candidates, including two core products: Pro-101-1 for burn treatment and Pro-101-2 for diabetic foot treatment [6]. Financial Performance - The company reported revenues of RMB 471,700 in 2023 and RMB 261,100 in 2024, with no revenue generated from product sales. The net losses for the same periods were RMB 105.2 million and RMB 212.3 million, respectively [7][9]. - Cumulative losses over the two years and nine months amounted to RMB 451.9 million [8]. Cash Flow Analysis - The net cash used in operating activities was RMB 57.9 million in 2023 and RMB 90.1 million in 2024, indicating ongoing cash outflows primarily due to R&D and administrative expenses [10].

Core Viewpoint - Four new stocks listed on the Hong Kong stock market experienced significant declines on their first trading day, marking a poor performance for new listings in 2023 [1] Group 1: Stock Performance - Ming Kee Hospital (02581.HK) fell by 49.46%, the largest drop among the new listings [1] - Impression Da Hong Pao (02695.HK) decreased by 35.28% [1] - Huazhi Biotechnology (02396.HK) saw a decline of 29.32% [1] - Nanhua Futures (02691.HK) dropped by 24.17% [1] Group 2: Market Context - The decline of Ming Kee Hospital exceeded the previous worst first-day performance of 47.67% by Conch Cement Technology (02560.HK) on January 9, setting a new record for the worst debut performance of new stocks in Hong Kong this year [1]

Core Viewpoint - Huazhong Biopharmaceutical Co., Ltd. (2396.HK) experienced a decline on its first day of trading, with shares dropping nearly 19% to HKD 31, resulting in a market capitalization of HKD 3.65 billion, despite an IPO pricing of HKD 38.2 and significant oversubscription in both public and international offerings [1] Company Overview - Established in 2012, Huazhong Biopharmaceutical is a China-based biopharmaceutical company focused on developing therapies, particularly protein drugs targeting medical needs and market opportunities [1] - The company's primary focus is on discovering, developing, and commercializing therapies for wound healing, currently centered around PDGF drugs [1] Financial Performance - For the fiscal years 2023 and 2024, as well as the first nine months of 2025, Huazhong Biopharmaceutical reported revenues of HKD 472,000, HKD 261,000, and HKD 0 respectively [1] - The company incurred losses of HKD 105 million, HKD 212 million, and HKD 134 million during the same periods, indicating no revenue or profit in the first three quarters of the current year [1]

Core Viewpoint - Huazhan Biotechnology (Qingdao) Co., Ltd. officially listed on the Hong Kong Stock Exchange, marking it as the 86th listed company in Qingdao and the second new listing of the year, following Taikaiying [1] Group 1: Company Overview - Huazhan Biotechnology, established in 2012 and headquartered in Qingdao, focuses on the research and development of protein drugs, particularly in the field of platelet-derived growth factor (PDGF) [2] - The company's core product, Pro-101-1, is the fastest PDGF candidate drug in clinical development for burn treatment in China, having completed Phase IIb clinical trials and expected to launch in China by 2027 [2] Group 2: Financial and Market Information - The offering price for Huazhan Biotechnology was set at HKD 38.20 per share, with a total global offering of 17.6488 million H shares, raising approximately HKD 670 million, and a net amount of about HKD 600 million after expenses [1] - On the first day of trading, the company's stock price faced pressure, closing at HKD 35.00 per share, a decline of 8.38% [1] Group 3: Use of Proceeds - The raised funds will primarily be used for clinical development and commercialization of core products, with approximately 61.8% allocated to Pro-101-1 and Pro-101-2, 18.8% for purchasing R&D and quality control equipment, and the remainder for other PDGF product development and operational funds [1] Group 4: Strategic Support and Impact - The company has received strong support from local government, with Qingdao Laoshang Technology Innovation Development Group holding a 9.09% stake as a significant strategic investor [2] - The listing is expected to accelerate the commercialization of core products, enhance brand influence, and attract capital and talent to the biopharmaceutical industry in Qingdao and Shandong, promoting regional industrial cluster development [2]

Group 1 - The Hang Seng Index rose by 0.20%, gaining 51 points to close at 25,742 points, while the Hang Seng Tech Index increased by 0.89% [1] - China Duty Free Group (01880) surged by 12% as duty-free shopping on Hainan's first day of closure increased by 61% year-on-year [1] - Lithium stocks continued to rise, with Tianqi Lithium (09696) up over 5% due to expectations of resumption of production, and Ganfeng Lithium (01772) increasing by 4.84% [1] - Jiaxin International Resources (03858) rose over 10% to reach a new high, benefiting from a more than 220% increase in tungsten powder prices this year [1] - Spot gold reached a new historical high, with Goldman Sachs reaffirming a bullish outlook on gold, leading to significant gains in gold stocks such as Lingbao Gold (03330) up 6.8% and China Gold International (02099) up 6.2% [1] - The optical communication sector showed strong performance, with Huiju Technology (01729) rising over 13% due to breakthroughs in optical computing chips, and Changfei Optical Fiber (06869) increasing by 11.01% [1] - Chip stocks strengthened in early trading, with the National Integrated Circuit Investment Fund's third phase focusing on IC substrate fields, leading to a rise of over 7% for SMIC (00981) and 5% for Hua Hong Semiconductor (01347) [1] - Pony.ai-W (02026) increased by over 9%, achieving single-vehicle profitability in Guangzhou, with two models of its seventh-generation vehicle now in production [1] Group 2 - Guoxia Technology (02655) surged over 16% as the company enters a new phase of global development, focusing on deepening "AI+" core technology research in energy storage [2] - WanGuo Gold Group (03939) rose nearly 7%, with its subsidiary Jinling Mining expected to become a world-class gold mine [3] - Goldwind Technology (02208) increased by nearly 5% as domestic wind turbine bidding prices recovered, with institutions optimistic about the profitability recovery of wind turbine manufacturers [4] - Four new stocks listed all fell below their issue prices, with Impression Dahongpao (02695) dropping 25%, Mingji Hospital (02581) down 42%, and Huazhi Biotechnology-B (02396) declining over 8% [4]

Group 1: Stock Market Performance - The Hang Seng Index rose by 0.20%, gaining 51 points to close at 25,742 points, while the Hang Seng Tech Index increased by 0.89% [1] - The Hong Kong stock market saw a trading volume of HKD 95.5 billion in the morning session [1] Group 2: Company Highlights - China Duty Free Group (01880) surged by 12% as duty-free shopping on the first day of Hainan's closure increased by 61% year-on-year [1] - Tianqi Lithium (09696) rose over 5% due to expectations of resumption of production following environmental assessment information disclosure [1] - Ganfeng Lithium (01772) increased by 4.84% [1] - Jiaxin International Resources (03858) climbed over 10%, reaching a new high, benefiting from a more than 220% increase in tungsten powder prices this year [1] - Gold stocks performed well, with Lingbao Gold (03330) rising by 6.8% and China Gold International (02099) increasing by 6.2% as spot gold reached a historical high [1] - Huizhu Technology (01729) surged over 13% due to breakthroughs in optical computing chip technology [1] - Zhongke Semiconductor (00981) rose over 7% as the National Integrated Circuit Investment Fund's third phase focuses on IC substrate [1] - Pony.ai-W (02026) increased by over 9%, achieving single-vehicle profitability in Guangzhou with two models of its seventh-generation vehicle in production [1] - Guoxia Technology (02655) surged over 16% as the company enters a new phase of global development, focusing on "AI+" energy storage core technology [2] - WanGuo Gold Group (03939) rose nearly 7% as its subsidiary Jinling Mining is expected to become a world-class gold mine [3] - Goldwind Technology (02208) increased nearly 5% as domestic wind turbine bidding prices recover, with institutions optimistic about the profitability of wind turbine manufacturers [4] Group 3: IPO Performance - Four new stocks listed all experienced declines, with Impression Dahongpao (02695) dropping by 25%, Mingji Hospital (02581) falling by 42%, and Huazhi Biotechnology-B (02396) decreasing by over 8% [4]

Group 1: New Stock Listings Performance - Four new stocks, including Impression Da Hong Pao, Huazhang Biotech, Mingji Hospital, and Nanhua Futures, debuted but all experienced a decline on their first trading day [1] Group 2: Huazhang Biotech - Huazhang Biotech opened at HKD 33.8, which is 11.5% lower than the IPO price of HKD 38.2, resulting in a loss of HKD 880 per lot of 200 shares [2] - The company focuses on wound healing therapies and is an unprofitable biotech firm specializing in developing protein drugs, particularly platelet-derived growth factor (PDGF) drugs [2] - The company did not attract cornerstone investors, with Huatai International and CITIC Securities serving as joint sponsors [3] Group 3: Mingji Hospital - Mingji Hospital opened at HKD 6.5, down 30.4% from the IPO price of HKD 9.34, leading to a loss of HKD 1,420 per lot of 500 shares [4] - The company operates as a large private profit-oriented hospital group in East China, primarily managing two tertiary hospitals in Nanjing and Suzhou, with a focus on orthopedics, cardiovascular, oncology, and reproductive medicine [4] - Cornerstone investors include He Rong Technology, He Fu (China), and Suzhou Zhanxing, collectively subscribing to 49.63% of the total offering [5] Group 4: Impression Da Hong Pao - Impression Da Hong Pao opened at HKD 3.26, which is 9.4% lower than the IPO price of HKD 3.6, resulting in a loss of HKD 340 per lot of 1,000 shares [6] - The company operates based on Wuyi Mountain tea culture, providing tourism performances and related services, with its core revenue source being the live performance "Impression Da Hong Pao," accounting for over 85% of its income [6] - The company was oversubscribed by over 3,400 times, with joint sponsors being Xingsheng International and Kaisen [6] Group 5: Nanhua Futures - Nanhua Futures opened at HKD 9.13, down 23.9% from the IPO price of HKD 12, leading to a loss of HKD 1,435 per lot of 500 shares [7] - The company is a futures brokerage listed on the A-share main board, primarily engaged in futures brokerage, investment consulting, asset management, and securities investment fund distribution, focusing on derivative business [7] - CITIC Securities is the sole sponsor for the company [7]

Core Viewpoint - Huazhang Biopharmaceutical-B (02396) has made its debut on the stock market with an initial share price of HKD 38.2, issuing 17.6488 million shares and raising approximately HKD 600 million in net proceeds. As of the report, the stock has dropped by 11.52% to HKD 33.8, with a trading volume of HKD 103 million [1]. Company Overview - Established in 2012, Huazhang Biopharmaceutical is a biopharmaceutical company headquartered in China, focusing on developing therapies, particularly protein drugs for indications with medical needs and market opportunities [1]. - The company's primary focus is on discovering, developing, and commercializing wound healing therapies, with a pipeline that includes ten candidate products, seven of which are PDGF candidates [1]. Product Pipeline - The two core products are Pro-101-1, aimed at treating burns, and Pro-101-2, intended for diabetic foot treatment, both of which are rhPDGF-BB drugs [1]. - According to a Frost & Sullivan report, as of the last feasible date, there are three PDGF drug pipelines in China, with no approved PDGF drugs available in the market [1]. - All PDGF pipelines are based on the PDGF-BB isoform, with two pipelines belonging to Huazhang Biopharmaceutical, which entered Phase II clinical trials for diabetic foot treatment in February 2022 and is expected to complete patient enrollment for Phase IIb clinical trials for treating second-degree and superficial burns by April 2025 [1].

每经AI快讯，12月22日，华芢生物-B（02396.HK）首挂上市，每股定价38.2港元，共发行1764.88万股 股份，每手200股，所得款项净额约6亿港元。截至发稿，华芢生物-B跌11.52%，报33.8港元，成交额 1.03亿港元。 ...

Core Viewpoint - Huazhang Biopharma-B (02396) has made its debut on the stock market with an initial share price of HKD 38.2, raising approximately HKD 600 million through the issuance of 17.6488 million shares, but the stock has seen a decline of 11.52% to HKD 33.8 at the time of reporting [1] Company Overview - Established in 2012, Huazhang Biopharma is a biopharmaceutical company based in China, focusing on the development of therapies, particularly protein drugs targeting medical needs and market opportunities [1] - The company's primary focus is on discovering, developing, and commercializing wound healing therapies, with a pipeline that includes ten candidate products, seven of which are PDGF candidates [1] Product Pipeline - The two core products in the pipeline are Pro-101-1 for treating burns and Pro-101-2 for treating diabetic foot, both of which are rhPDGF-BB drugs [1] - According to a Frost & Sullivan report, as of the last feasible date, there are three PDGF drug pipelines in China, with no PDGF drugs approved in the country [1] - All PDGF pipelines are based on the PDGF-BB isoform, with two pipelines belonging to Huazhang Biopharma, which entered Phase II clinical trials for diabetic foot treatment in February 2022 and is expected to complete patient enrollment for Phase IIb clinical trials for treating second-degree and superficial burns by April 2025 [1]